FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AUROPHARMA

778.5
-20.6 (-2.58%)
Updated 03:29 23/09 IST

AUROPHARMA Buy or Sell - FrontPage Forums

4 Users have submitted 4 trade ideas of Rs. 878,198.75 for AUROPHARMA
Disclaimer
100% Bullish
0% Bearish

AUROPHARMA Buy or Sell - Brokerage Reports

No. of reports in last year
17
No. of analysts
8
Average Consensus Forecast
657.82
Consensus Potential
-28.23%
See AUROPHARMA Share Price Targets >>

AUROPHARMA Ratings

Long term AUROPHARMA rating by FrontPage users
4.4/5 (14 Ratings)
Find answers to all your questions on live AUROPHARMA message board: Is AUROPHARMA buy or sell? Should I buy AUROPHARMA shares? Why are AUROPHARMA shares falling? Should I invest in AUROPHARMA stock?

  1. Home
  2. AUROPHARMA Forum

AUROPHARMA Share Price Discussion

R
Reputation: 206 • Just now

Sharekhan target on AUROPHARMA
Date: 22-Sep-20 Broker: Sharekhan Price @ Call: 793.73 Target: 975 Potential: 0.23% Recommendation: BUY
Like
Reply
R
Reputation: 206 • Just now

Dolat Capital target on JBMA
Date: 22-Sep-20 Broker: Dolat Capital Price @ Call: 214.45 Target: 373 Potential: 0.74% Recommendation: BUY
Like
Reply
R
Reputation: 206 • Just now

Nirmal Bang target on CUB
Date: 23-Sep-20 Broker: Nirmal Bang Price @ Call: 135 Target: 178 Potential: 0.32% Recommendation: BUY
Like
Reply
N
Reputation: 6,148 • Just now
The world should get a COVID-19 vaccine by early 2021, says Microsoft founder Bill Gates
"I am optimistic that by early next year, of the six western constructs, probably three or four will have shown safety and efficacy, and four of those can be made at large scale and low cost, including AstraZeneca, Johnson & Johnson, Novavax and Sanofi," the co-chair of the Bill and Melinda Gates foundation told the ET Global Business Summit.
The Economic Times
Like
Reply

TITAN - 1362637

BUY WITH
POSITIONAL SL 1098
Like
Reply

UBL - 1362634
BUY ABOVE THE BREAKOUT OF 968 WITH GOOD VOLUME.
Like
Reply
K
Reputation: 511 • Yesterday 5:22 AM

TODAY LIVE NATURAL GAS VIEW UPDATE....
NATURAL GAS BUY LEVAL TRIGGER NATURAL GAS FROM 135.40 NATURAL GAS FIREEEEEEEEEEE HIT.....156+++++🤩🤩🤩🤩🔥💪💪💪🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
(BOOKED 5,000++++RUPESS@2LOT NATURAL GAS)🤩🤩🤩🤩🔥💪💪💪💪🔥🔥🤩🤩🤩🔥🔥💪💪🔥🔥🔥🔥
Like
Reply
K
Reputation: 511 • Yesterday 5:22 AM

TODAY LIVE CRUDE VIEW GIVEN.....
CRUDE SELL TRIGGER CRUDE OIL FROM 2908 DAY LOW HIT.......2894+++++🤩🤩🤩🤩🔥🔥💪💪🔥🔥🔥🔥🔥🔥🔥
(BOOKED 2800++++RUPESS@2LOT MEGA LOT CRUDE OIL)🤩🤩🤩🤩🤩🔥🔥💪💪🔥🔥🔥🔥🔥🔥🔥
Like
Reply
K
Reputation: 511 • Yesterday 5:21 AM

TODAY LIVE GOLD VIEW GIVEN.....
GOLD SELL LEVAL TRIGGER GOLD FROM 50050 GOLD CRASSHHHHHHHHH LOW HIT........49510++++++🤩🤩🤩🤩🤩🤩🔥🔥🔥💪💪💪💪🔥🔥🔥🔥🔥🔥🔥🔥
(GOLD CRASSHHHHHH 540++++POINTSSSS)🤩🤩🤩🤩🤩🔥🔥💪💪💪🔥🔥🔥🔥🔥🔥🔥
Like
Reply
S
Reputation: -27,983 • Yesterday 5:20 AM
2
Reply
S
Reputation: -27,983 • Yesterday 5:19 AM
1
Reply

INDIGO - 1362613
BUY NEAR 1262-1265

DO NOT BUY IF THE STOCKS STARTS FALLING. ----->> BUY ON THE RISE !!
1
Reply
CS Advisory in NIFTY-BANK
#NIFTYBANK Buy SEP 21500 PE ABOVE 420 TGT OPEN ...

698 HIGH 💸💲💲💰💰💲
420 TO 698
CS ALWAYS GREEN MTM 💚💰💚💰💚💸
Like
Reply
CS Advisory in NIFTY-50
#NIFTY50 BUY NIFTY 11200 PE 24 SEP ABOVE 60 TGT...

60 TO 181 HIGH 💸💲💲💰💰💲💰💰
DOUBLE+++ POINT
CS ALWAYS GREEN MTM 💚💰💚💰💚
Like
Reply (1)
See all replies
Ashwita R @ashwita
Just now

High doesn't matter.. close price just 76

NAUKRI - 1362606

BUY ABOVE 3388 WITH
SL BELOW LOWER TRENDLINE
Like
Reply

SEE YOU ALL WITH POSITIVITY AGAIN ....

1
Reply
N
Reputation: 6,148 • Yesterday 4:56 AM
US health secretary says AstraZeneca trial in United States remains on hold: Report
Alex Azar said that the FDA's investigation, which has continued even after the trial has resumed outside of the United States, shows that the agency takes safety of the vaccine seriously.
The Economic Times
Like
Reply

Type
Sell
Instrument
NATURALGAS 25SEP20 FUT
Entry Price
₹154
Price@Trade
₹154
Target Price
₹140
Stop Price
₹157
Valid Till
Sep 24, 2020 11:20 AM
Margin
₹68,656.25 approx for 1250 Qty
Status
Active
Like
Reply
K
Reputation: -33,789 • Yesterday 4:54 AM

BHARTIARTL - chart - 1362591
Look at this chart how price came down from higher levels and am expecting more down side in coming days. keep stop loss above 440 closing basis and look for target around 400 in coming days.


keep learning
keep sharing
keep growing
3
Reply (1)
See all replies

@king999 price will take support on trendline can expect the movement of 450++ rsi in oversold level
Route Mobile Share Price Surges 18% 🔥 | Stock Zooms 134% 🤑 | Route Mobile Latest News
Join Free Telegram Channel (Jagdish Stock Market Classes) : https://t.me/jagdishjha # Authorized Partners : A/C Opening Link 1. Zerodha : https://zerodha.com...
YouTube
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AUROPHARMA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,051.74
    Enterprise Value50,495.97
    Price to Earnings18.01
    Price to Book Value4.06
    Return on Capital Employed0.17
    Return on Equity0.18
    Face Value1
    Dividend Yield0.01
  • AUROPHARMA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    22-Sep-20SharekhanBuy975
    7-Sep-20Axis DirectBuy940
    5-Jun-20Prabhudas LilladherAccumulate838
    22-Apr-20Nirmal BangAccumulate719
    21-Apr-20ICICIdirect.comBuy770
    AUROPHARMA Brokerage Price Target
  • AUROPHARMA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 23810813.65771.3780.2
    Sep 21835857.9785.8792.35
    Sep 18815.65840815.65828.1
    Sep 17826.95827807810.8
    Sep 16844851.35823.1832.1
  • AUROPHARMA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹816.77
    30 Day Moving Average₹838.57
    50 Day Moving Average₹839.88
    100 Day Moving Average₹789.26
    200 Day Moving Average₹633.43
  • AUROPHARMA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue10,2709,607.050.07
    Operating Profit2,6702,373.950.12
    Profit Before Tax2,3432,178.570.08
    Net Income1,8131,706.760.06
  • AUROPHARMA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds11,3519,9830.14
    Total Liabilities6,7906,1970.1
    Total Assets18,14116,1800.12
  • AUROPHARMA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity9142,457.2-0.63
    Cash from Investing Activity-981-1,542.05-0.36
    Cash from Financing Activity440-1,328.99-1.33
    Net Cash Flow372-413.84-1.9
  • AUROPHARMA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.110.13
    Return on Equity0.180.2
    Return on Capital Employed0.170.19
  • AUROPHARMA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.27
    3 Year CAGR Growth in Operating Profit0.19
    3 Year CAGR Growth in EBIDTA0.19
    3 Year CAGR Growth in Net Income0.2
    3 Yr CAGR Growth - Diluted EPS-0.4
  • AUROPHARMA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.89
    5 Year CAGR Growth in Operating Profit1.79
    5 Year CAGR Growth in EBIDTA1.79
    5 Year CAGR Growth in Net Income2.66
    3 Yr CAGR Growth - Diluted EPS0.82
  • AUROPHARMA - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 5:53 AM
    Buy Aurobindo Pharma; target of Rs 975: Sharekhan
    Moneycontrol
    NewsBot
    Sep 22 5:01 AM
    stocks to buy | where to invest: 4 sectors to buy into in a market correction: Pankaj Pandey
    The Economic Times
    NewsBot
    Sep 15 12:13 PM
    Aurobindo Pharma ties up with BIRAC to develop COVID-19 vaccine
    Moneycontrol
    NewsBot
    Sep 15 5:56 AM
    Stock market update: Nifty Pharma index up 2%; Dr Reddy's Lab jumps 4%
    The Economic Times
    NewsBot
    Sep 3 7:46 AM
    Stock market update: Nifty Pharma index climbs 1%; Biocon rises 3%
    The Economic Times
    NewsBot
    Aug 26 6:06 AM
    Stock market update: Pharma stocks fall; Torrent Pharma loses 2%
    The Economic Times
    NewsBot
    Aug 25 5:56 AM
    Stock market update: Pharma stocks down; Cadila Healthcare sheds over 1%
    The Economic Times
    NewsBot
    Aug 20 12:53 PM
    Hot Stocks | Aurobindo Pharma, Cummins India, LIC Housing Finance can return up to 12% return in short-term
    Moneycontrol
    NewsBot
    Aug 19 4:48 AM
    Buy Aurobindo Pharma; target of Rs 1027: KR Choksey
    Moneycontrol
    NewsBot
    Aug 17 10:48 AM
    Buy Aurobindo Pharma; target of Rs 1000: Emkay Global Financial
    Moneycontrol
  • AUROPHARMA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • AUROPHARMA - More Information

    keyboard_arrow_down

    Aurobindo Pharma Ltd:
    Aurobindo Pharma Limited is propagating its business in researching, developing, manufacturing, and selling of several pharmaceutical products in India. Producing a significant variation in oral and injectable generic formulations, and active pharmaceutical ingredients and manufacturing peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries.
    Along with providing custom research and producing services to biotech and pharmaceutical community the company is reigning over antibiotic, anti-retroviral, cardiovascular, central nervous system, gastroenterological, anti-diabetic, and anti-allergy areas. Besides that, the company is manufacturing proteins, vitamins, minerals, and supplements, sports drinks etc.
    The company is exporting its products to almost 150 countries, including the U.S. and Europe along with serving multinational companies. The company is amongst the largest producers of Ampicillin and Cloxacillin in India. Aurobindo Pharma Limited was established in 1986 as a private limited company and headquartered in Hyderabad, Andhra Pradesh, India.
    About Company Information:
    Aurobindo Pharma was converted to a public limited firm in the year of 1992, after six years from its inception. The company built A CMIC chloride manufacturing unit at Pashamylaram near Hyderabad in the same year. The company started to issue bonus shares in a ratio of 1:1, 2:1 and 7:20 in ’92, ’93 and ’94 respectively. In 1993 the company built up another two plants at Bollaram and Kukatpally near Hyderabad. In 1994, the company increased the capacity at Pondicherry Unit from 204 TPA to 300 TPA along with increasing the installed capacity of its Bollaram unit from 78 TPA to 84 TPA. An amalgamation took place between the company and Chaitanya Organics Pvt. Ltd. in April 1994.
    Glaxo (India), a subsidiary of the U.K. based multinational Glaxo went for an alliance with Aurobindo Pharma in 1997, which increased the number of capsules and bulk drug up to 300 million and 840 tons respectively. In 1998, the company introduced Auronim Suspension in its pediatric segment. In FY 1999-2000, the company added a large section of Cephalosporins (Oral & Sterile) and anti-viral along with macrolides, quinolones, semi-synthetic penicillin, formulating for both the domestic and export market.
    During 2001-02 79% stake in Ranit Pharma Company were acquired by Aurobindo Pharma Ltd. A 50:50 joint venture firm of the company, namely Citadel Aurobindo Biotech Ltd, launched Aztreonam, a Monabactam Beta-lactam antibiotics as a debut in the Indian Pharma Market, TREONAM being the brand name, in 2003. In 2005-06, the company intervened in the markets of USA & Europe, with participation in the PEPFAR program, initiated by the US Govt. In March 2007, the FDA (U.S.) finally approved the company’s Didanosine Oral Suspension (Pediatric Powder) 10 mg/ml.
    Aurobindo Pharma acquired Moore and Carmiooro, the high profile OTC brands from TAD in 2008. AstraZeneca, a leading biopharmaceutical company in the international market, had gone for an agreement with Aurobindo Pharma, for supplying solid dosage and sterile products in 2010. A deal took place between Aurobindo Pharma and National Pharmaceutical Group Corporation, China, for launching the subsidiary Aurobindo (Datong) BioPharma Co Ltd, China (ADBPL).
    In April 2014, Aurobindo Pharma declared the completion of several business operations of Europe’s Actavis plc, an internationally recognized pharmaceutical company, manufacturing and supplying generic, brand and biosimilar products. On November 2016, a subsidiary of Aurobindo Pharma Ltd in France, namely Arrow Generiques SAS, signed an agreement to gain the right, title and interest in its products Calcium and Calcium Vitamin D3 in the French market, including the use of Teva Pharmaceutical Industries OROCAL trademark.
    On January 2017, Aurobindo Pharma declared about setting up a binding agreement by and through its solely owned subsidiary, Agile Pharma B.V., Netherlands, for acquiring Generis Farmaceutica SA, a pharmaceutical company of Portugal, against a lump sum of 135 million Euro totally including net working capital of 21.7 million Euro. On February 2017, four-cell culture derived biosimilar products from T.L. Biopharmaceutical AG were acquired by Aurobindo Pharma as declared by the company.
    How Aurobindo Pharma Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Aurobindo Pharma Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Aurobindo Pharma Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020